Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer
about
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.Pancreatic ductal adenocarcinoma: is a cure possible?Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Drugging RAS: Know the enemy.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of RasTissue specificity of in vitro drug sensitivity.Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.The Generation and Application of Patient-Derived Xenograft Model for Cancer Research.Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems.Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-scale, Ion-Current-Based Quantitative Proteomics (IonStar).Patient-derived organoid models help define personalized management of gastrointestinal cancer.Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?A microfluidics platform for combinatorial drug screening on cancer biopsies.Olfactory Receptors as Biomarkers in Human Breast Carcinoma Tissues.Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
P2860
Q38723234-43915FAB-0393-42F0-A60C-FFEC9E81FB03Q38749836-A2B3F77E-17C9-4EEF-9C4F-79127A69D8BBQ39028343-2F65D251-049C-44EF-8F6C-351C1A0272B7Q39182842-2EF17C34-6356-4A40-AC89-37B3CF1C2C90Q39204274-D146DDB1-401E-4623-952D-B3FB9703C8F1Q42353674-C6206E99-6E3E-4B0C-9FE1-D66F4F38DFD3Q47655442-6FC11A9C-E727-4A4B-A047-EFD27CB1B611Q48675205-814C2CFA-500F-4041-BBDB-D10F68E25A47Q49284173-685A3CF9-BB85-485D-B83C-F2618E71B099Q49494945-AE8CAA92-C040-4BCC-9A23-DBED509DA537Q49547342-8F8A2C24-5654-44ED-9F7E-7E3DCAADDDC4Q49547506-4BA40265-0723-45A9-AEF6-53E11C8F1060Q49874345-EB2BC788-EEDB-44C4-AF6E-0CE3BF1E99A0Q50010294-833F7BC7-002B-411F-9167-4DD1E26422FEQ54277914-C40CE726-4254-4E56-B80A-3AE68B55B90EQ55363674-F6C13078-D868-4271-AC61-ADC1C992A1CAQ55365224-006DB475-4B8F-43AD-BA63-015F91C04F7BQ58792021-4A1D3E60-4442-400D-82D0-B930B9C12104
P2860
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Integrated Patient-Derived Mod ...... abilities of Pancreatic Cancer
@en
Integrated Patient-Derived Mod ...... bilities of Pancreatic Cancer.
@nl
type
label
Integrated Patient-Derived Mod ...... abilities of Pancreatic Cancer
@en
Integrated Patient-Derived Mod ...... bilities of Pancreatic Cancer.
@nl
prefLabel
Integrated Patient-Derived Mod ...... abilities of Pancreatic Cancer
@en
Integrated Patient-Derived Mod ...... bilities of Pancreatic Cancer.
@nl
P2093
P2860
P1433
P1476
Integrated Patient-Derived Mod ...... abilities of Pancreatic Cancer
@en
P2093
Agnieszka K Witkiewicz
Bruce Posner
Cody Eslinger
Elizabeth McMillan
Erik S Knudsen
Gordon B Mills
Uthra Balaji
William Conway
P2860
P304
P356
10.1016/J.CELREP.2016.07.023
P577
2016-08-04T00:00:00Z